Sign In
Buy LXRX
$2.31
-0.0300 (-1.28%)
At Close: Jul 31, 2026
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
08:30am, Wednesday, 03'rd Sep 2025
THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact o
THE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled Ana
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
08:30am, Wednesday, 27'th Aug 2025
THE WOODLANDS, Texas, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at Citi's Biopharma Bac
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know
01:01pm, Friday, 08'th Aug 2025
Lexicon (LXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Lexicon (LXRX) Q2 Revenue Soars 1,706%
04:50pm, Wednesday, 06'th Aug 2025
Lexicon (LXRX) Q2 Revenue Soars 1,706%
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call Transcript
12:39pm, Wednesday, 06'th Aug 2025
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Craig B. Granowitz - Senior VP & Chief Medical Officer Lisa M.
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates
09:45am, Wednesday, 06'th Aug 2025
Lexicon Pharmaceuticals (LXRX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to a loss of $0.17 per share a year
Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
07:30am, Wednesday, 06'th Aug 2025
Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
08:00am, Thursday, 31'st Jul 2025
THE WOODLANDS, Texas, July 31, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Nasdaq's listing qualifications staff has determined that the closing bid pric
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
08:00am, Wednesday, 23'rd Jul 2025
THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, Au
Patient insights informed the development of pilavapadin, Lexicon's investigational, novel, non-opioid treatment for people suffering from DPNP Patient insights informed the development of pilavapadin
Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a re
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
08:30am, Wednesday, 18'th Jun 2025
THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
08:00am, Thursday, 29'th May 2025
THE WOODLANDS, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2025 Jefferies Gl
Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively enro
